Clinical Trials Logo

Clinical Trial Summary

This is a Phase IIa, open-label, multiple dose, study in patients with PNH who have not received eculizumab (Soliris ®) in the past. A single cohort of subjects is planned for evaluation.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03593200
Study type Interventional
Source Apellis Pharmaceuticals, Inc.
Contact
Status Completed
Phase Phase 2
Start date August 16, 2018
Completion date October 22, 2019

See also
  Status Clinical Trial Phase
Terminated NCT04725812 - Complement Regulation to Undo Systemic Harm in Preeclampsia Phase 2
Completed NCT02598583 - Dose-Escalation Study of ALXN1210 IV in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Phase 1/Phase 2
Recruiting NCT05539248 - A Study on the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of CAN106 in Subjects With PNH Phase 1/Phase 2
Active, not recruiting NCT03460301 - Observational of PNH Type Cells in Korean Patients With Bone Marrow Failure Syndrome and Having Hemolytic PNH N/A
Completed NCT01412047 - Paroxysmal Nocturnal Hemoglobinuria Human Anti-Human Antibodies Study N/A
Completed NCT02605993 - Open-label, Multiple Ascending Dose Study of Ravulizumab (ALXN1210) in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Phase 2
Completed NCT05095168 - Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Single Ascending Dose (SAD) of CAN106 Administered Intravenously (IV) in Healthy Subjects Phase 1
Active, not recruiting NCT04702568 - A Long Term Safety Study of BCX9930 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH) Phase 2
Completed NCT05337683 - A Retrospective Chart Review Study to Evaluate the Impact of Eculizumab in Korean PNH Patients
Active, not recruiting NCT03531255 - Pegcetacoplan Long Term Safety and Efficacy Extension Study Phase 3
Completed NCT05884060 - Retrospective Chart Review Screening Algorithm to Assess the Prevalence of PNH-clones
Available NCT05982938 - Danicopan Early Access Program